Especially in the most famous Q-SYMBIO study to date, the authors didn’t find statistically significant differences in the primary short-term endpoints (including the 6-minute walk test, NYHA functional class, and NT-pro BNP) between CoQ10 and placebo-treated HF patients at 4-month follow-up. This evidence concerns the gene NPPB and hydrops fetalis.